IBX Stock Overview
Provides medical imaging technologies using magnetic resonance. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Imagion Biosystems Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.021 |
| 52 Week High | AU$0.37 |
| 52 Week Low | AU$0.018 |
| Beta | 1.94 |
| 1 Month Change | -41.67% |
| 3 Month Change | -19.23% |
| 1 Year Change | -93.82% |
| 3 Year Change | -99.27% |
| 5 Year Change | -97.08% |
| Change since IPO | -99.67% |
Recent News & Updates
Recent updates
Here's Why We're Watching Imagion Biosystems' (ASX:IBX) Cash Burn Situation
Dec 13
Here's Why We're Watching Imagion Biosystems' (ASX:IBX) Cash Burn Situation
Aug 30We're Not Very Worried About Imagion Biosystems' (ASX:IBX) Cash Burn Rate
Feb 22We're Hopeful That Imagion Biosystems (ASX:IBX) Will Use Its Cash Wisely
Sep 09We're Not Very Worried About Imagion Biosystems' (ASX:IBX) Cash Burn Rate
May 03Imagion Biosystems (ASX:IBX) Has Rewarded Shareholders With An Exceptional 582% Total Return On Their Investment
Feb 28Here's Why We're Not Too Worried About Imagion Biosystems' (ASX:IBX) Cash Burn Situation
Jan 06Shareholder Returns
| IBX | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -12.5% | -0.4% | -2.0% |
| 1Y | -93.8% | 0.9% | 7.8% |
Return vs Industry: IBX underperformed the Australian Medical Equipment industry which returned 0.9% over the past year.
Return vs Market: IBX underperformed the Australian Market which returned 7.8% over the past year.
Price Volatility
| IBX volatility | |
|---|---|
| IBX Average Weekly Movement | 30.4% |
| Medical Equipment Industry Average Movement | 9.0% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.8% |
| 10% least volatile stocks in AU Market | 3.1% |
Stable Share Price: IBX's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: IBX's weekly volatility has increased from 21% to 30% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | n/a | imagionbiosystems.com |
Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers, as well as in preclinical stage to treat prostate, ovarian, brain, and pancreatic cancer.
Imagion Biosystems Limited Fundamentals Summary
| IBX fundamental statistics | |
|---|---|
| Market cap | AU$3.83m |
| Earnings (TTM) | -AU$6.32m |
| Revenue (TTM) | AU$5.92m |
0.7x
P/S Ratio-0.7x
P/E RatioIs IBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBX income statement (TTM) | |
|---|---|
| Revenue | AU$5.92m |
| Cost of Revenue | AU$3.38m |
| Gross Profit | AU$2.54m |
| Other Expenses | AU$8.86m |
| Earnings | -AU$6.32m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.031 |
| Gross Margin | 42.95% |
| Net Profit Margin | -106.79% |
| Debt/Equity Ratio | -60.1% |
How did IBX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 11:41 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Imagion Biosystems Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|